From clinician scientist to nonprofit CEO

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

I was a practicing pediatric hematologist oncologist and researcher for 21 years. As a doctor, it was a tremendous privilege to be invited into the lives of patients and families dealing with blood cancers and be entrusted with their care. As a researcher, it was incredibly rewarding to help bring more effective blood cancer therapies to kids. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
E. Anders Kolb, MD
President and CEO, The Leukemia and Lymphoma Society
Table of Contents

YOU MAY BE INTERESTED IN

FDA has granted full approval of Komzifti (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Komzifti is the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated AML, a devastating blood cancer with limited treatment options.
E. Anders Kolb, MD
President and CEO, The Leukemia and Lymphoma Society

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login